loading
Schlusskurs vom Vortag:
$37.06
Offen:
$37.33
24-Stunden-Volumen:
478.11K
Relative Volume:
0.65
Marktkapitalisierung:
$2.08B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
3.1479
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
+2.17%
1M Leistung:
-1.43%
6M Leistung:
+6.87%
1J Leistung:
-18.34%
1-Tages-Spanne:
Value
$35.67
$37.50
1-Wochen-Bereich:
Value
$26.75
$37.86
52-Wochen-Spanne:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Firmenname
Agios Pharmaceuticals Inc
Name
Telefon
617-649-8600
Name
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
488
Name
Twitter
@AgiosPharma
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
AGIO's Discussions on Twitter

Vergleichen Sie AGIO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
35.76 2.19B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
366.54 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.00 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
438.93 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
661.83 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.18 35.49B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-24 Eingeleitet H.C. Wainwright Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-09-27 Herabstufung Leerink Partners Outperform → Market Perform
2024-02-08 Eingeleitet Cantor Fitzgerald Overweight
2023-02-03 Eingeleitet Piper Sandler Overweight
2022-11-17 Hochstufung Goldman Sell → Neutral
2022-07-27 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-12-03 Eingeleitet BofA Securities Buy
2021-07-30 Herabstufung Goldman Neutral → Sell
2021-07-01 Eingeleitet Raymond James Mkt Perform
2021-06-10 Eingeleitet H.C. Wainwright Buy
2021-03-01 Herabstufung JP Morgan Overweight → Neutral
2021-03-01 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-02-26 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-10-22 Hochstufung Barclays Equal Weight → Overweight
2020-03-04 Eingeleitet Barclays Equal Weight
2019-11-26 Eingeleitet Cantor Fitzgerald Overweight
2019-09-23 Hochstufung Guggenheim Neutral → Buy
2019-05-23 Fortgesetzt Goldman Neutral
2019-02-15 Hochstufung SVB Leerink Mkt Perform → Outperform
2018-09-25 Eingeleitet Leerink Partners Mkt Perform
2018-05-23 Eingeleitet Citigroup Buy
2018-04-11 Bestätigt Credit Suisse Outperform
2018-02-15 Bestätigt Needham Buy
2018-02-15 Bestätigt SunTrust Buy
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-08-10 Bestätigt Needham Buy
2017-08-08 Bestätigt SunTrust Buy
2017-08-02 Hochstufung Leerink Partners Mkt Perform → Outperform
2017-06-26 Herabstufung Janney Buy → Neutral
2017-01-17 Hochstufung Oppenheimer Perform → Outperform
2016-10-24 Eingeleitet Needham Buy
2016-06-13 Hochstufung JP Morgan Neutral → Overweight
2016-05-18 Bestätigt SunTrust Buy
Alle ansehen

Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten

pulisher
Aug 09, 2025

Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN

Aug 09, 2025
pulisher
Aug 08, 2025

Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance

Aug 08, 2025
pulisher
Aug 05, 2025

TD Cowen reiterates Buy rating on Agios Pharma stock amid safety concerns - Investing.com Canada

Aug 05, 2025
pulisher
Aug 05, 2025

Agios (AGIO) Q2 Revenue Jumps 45% - AOL.com

Aug 05, 2025
pulisher
Aug 05, 2025

Agios: Patients’ deaths don’t alter Pyrukynd’s benefit-risk profile - BioWorld MedTech

Aug 05, 2025
pulisher
Aug 05, 2025

Report of Patient Deaths Sends Agios Shares Seesawing - BioSpace

Aug 05, 2025
pulisher
Aug 05, 2025

Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

SFDA approves Agios Pharma’s Pyrukynd for thalassemia - Yahoo Finance

Aug 05, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data By Investing.com - Investing.com Nigeria

Aug 04, 2025
pulisher
Aug 04, 2025

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia - The Manila Times

Aug 04, 2025
pulisher
Aug 04, 2025

Breakthrough: Saudi Arabia Approves First-Ever Oral Treatment for All Adult Thalassemia Patients - Stock Titan

Aug 04, 2025
pulisher
Aug 04, 2025

Chartists See Breakout Potential in Agios Pharmaceuticals Inc.Fast Exit and Entry Strategy Guide Offered - beatles.ru

Aug 04, 2025
pulisher
Aug 04, 2025

Agios evaluating fourth Pyrukynd case after analyst report - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharma’s PYRUKYND Approved by Saudi Authority - TipRanks

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals addresses analyst report on PYRUKYND safety data - Investing.com

Aug 04, 2025
pulisher
Aug 04, 2025

Agios Pharmaceuticals: Navigating Pyrukynd's Thalassemia PDUFA and Sickle Cell Pipeline Risks Amid Recent Valuation Pressure - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Agios stock falls on Pyrukynd-related deaths (AGIO:NASDAQ) - Seeking Alpha

Aug 04, 2025
pulisher
Aug 04, 2025

Agios shares drop after report notes deaths of Pyrukynd patients By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 04, 2025

What makes Agios Pharmaceuticals Inc. stock price move sharplyMarket-leading profit generation - Jammu Links News

Aug 04, 2025
pulisher
Aug 03, 2025

How strong is Agios Pharmaceuticals Inc. company’s balance sheetBuild a winning investment portfolio - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Agios Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding risk-reward balance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Agios Pharmaceuticals Inc. stockMaximize gains with proven stock analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Agios Pharmaceuticals Inc. stockConsistent high-performance stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Agios Pharmaceuticals Inc. company’s key revenue driversCapitalize on fast-moving stock opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Agios Pharmaceuticals Inc.Superior investment outcomes - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Agios Pharmaceuticals Inc. stock expected to show significant growthAchieve rapid portfolio appreciation today - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is Agios Pharmaceuticals Inc. company’s growth strategyBuild wealth steadily with proven strategies - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What are the technical indicators suggesting about Agios Pharmaceuticals Inc.Capitalize on market momentum for maximum gains - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates - MSN

Aug 02, 2025
pulisher
Aug 02, 2025

Agios Pharmaceuticals Q2 2025: Unraveling Key Contradictions in Safety, Spending, and Pediatric Strategy - AInvest

Aug 02, 2025
pulisher
Aug 01, 2025

Agios expects modest full-year 2025 revenue growth with PYRUKYND thalassemia launch pending FDA approval - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Why is Agios Pharmaceuticals Inc. stock attracting strong analyst attentionDaily Trading Forecasts From AI Tools - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $50 to $65 - 富途牛牛

Aug 01, 2025
pulisher
Aug 01, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 01, 2025
pulisher
Aug 01, 2025

Agios 2025 Q2 Earnings Misses Targets as Net Income Declines 16.5% - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada

Aug 01, 2025
pulisher
Aug 01, 2025

Agios Pharmaceuticals Inc (AGIO) Q2 2025 Earnings Call Highlight - GuruFocus

Aug 01, 2025
pulisher
Aug 01, 2025

Agios Pharmaceuticals: Q2 Earnings Snapshot - Greenwich Time

Aug 01, 2025
pulisher
Aug 01, 2025

Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus

Aug 01, 2025
pulisher
Jul 31, 2025

Agios Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat

Jul 31, 2025
pulisher
Jul 31, 2025

Agios Pharmaceuticals: Navigating Earnings Volatility for Long-Term Growth in Rare Disease Therapeutics - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Earnings call transcript: Agios Pharm Q2 2025 earnings miss EPS, stock dips - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

Jul 31, 2025
pulisher
Jul 31, 2025

Agios Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 31, 2025
pulisher
Jul 31, 2025

How many analysts rate Agios Pharmaceuticals Inc. as a “Buy”Top Growth Target Finder To Watch Now - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Agios Pharmaceuticals Q2 2025 Revenue Beats Estimates: A Glimmer of Growth in a Continuously Loss-Making Biotech - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times

Jul 31, 2025
pulisher
Jul 31, 2025

Agios Pharmaceuticals Reports $12.5 Million in Q2 2025 PYRUKYND® Revenues and Highlights Key Regulatory Developments - Quiver Quantitative

Jul 31, 2025
pulisher
Jul 30, 2025

Agios Pharmaceuticals: Earnings Beat and Pipeline Offer Glimmers of Hope in Biotech's Volatile Landscape - AInvest

Jul 30, 2025
pulisher
Jul 29, 2025

Intrahepatic Cholangiocarcinoma Market: Epidemiology, - openPR.com

Jul 29, 2025
pulisher
Jul 29, 2025

Intrahepatic Cholangiocarcinoma Market: Epidemiology, Pipeline Products, Companies Working, DelveInsight | Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bay - Barchart.com

Jul 29, 2025

Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$78.39
price up icon 0.24%
$37.58
price up icon 1.54%
$109.55
price up icon 0.23%
$28.66
price up icon 2.10%
$111.66
price up icon 0.28%
biotechnology ONC
$288.18
price down icon 3.39%
Kapitalisierung:     |  Volumen (24h):